Results 111 to 120 of about 1,367,754 (318)

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

open access: yesMolecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain   +10 more
wiley   +1 more source

Chemotherapy for early-stage gastrointestinal lymphoma

open access: yes, 1991
A total of 176 patients with gastrointestinal lymphomas were reviewed. According to a modified staging classification, 51 of them had stage I/II disease and the remaining 125 had stage III/IV disease.
Todd, D   +5 more
core   +1 more source

In vitro Ceftaroline Activity against Major Bacterial Pathogens n Russia: Results of Multicenter Study [PDF]

open access: yesКлиническая микробиология и антимикробная химиотерапия, 2015
Background. Ceftaroline is a new broad-spectrum cephalosporin with in vitro activity against Gram-positive pathogens, including MRSA, and common Gram-negative pathogens.
Kozlov R.S.   +11 more
doaj  

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

open access: yesMolecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu   +10 more
wiley   +1 more source

Diabetes alone should not be a reason for withholding adjuvant chemotherapy for stage III colon cancer

open access: yes, 2011
Background: With increasing prevalence of diabetes mellitus and colon cancer, the number of patients suffering from both diseases is growing, and physicians are being faced with complicated treatment decisions.
Wouter M. W. Dercksen   +11 more
core   +1 more source

Chemotherapy adjuvant and chemotherapy-induced neutropenia

open access: yesTaiwanese Journal of Obstetrics and Gynecology, 2022
Yiu-Tai Li, Szu-Ting Yang, Peng-Hui Wang
openaire   +3 more sources

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

open access: yesMolecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Chemotherapy treatment for HER2 positive and triple negative breast cancer

open access: yes, 2019
Breast cancer is the most prevalent cancer among women worldwide. This thesis will represent the neoadjuvant and adjuvant chemotherapy treatment for triple negative breast cancer and HER2 positive breast cancer.
Kahala, Dolev
core  

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

open access: yesMolecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak   +10 more
wiley   +1 more source

Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer

open access: yes, 2017
BACKGROUND/AIMS: Palliative chemotherapy is the main treatment for advanced biliary tract cancer (BTC). However, there is a lack of established second-line chemotherapy to treat disease progression after first-line chemotherapy.
정장한   +8 more
core   +1 more source

Home - About - Disclaimer - Privacy